Project Twenty21 prices to remain the same next month as talks ongoing

Estimated reading time: 2 minutes

Project Twenty21 has confirmed that prescription prices won’t change as planned in March, as discussions continue.

In its latest newsletter to patients, Project Twenty21 has said that changes to its pricing model will not go ahead as expected on 1 March, 2022.

Discussions are said to be “going well” with the project’s licensed-producer partners about the price review. 

In January Drug Science announced several changes to its observational study, which aims to create the UK’s largest body of evidence for the safety and efficacy of medical cannabis.   

This included changes to the pricing model for patients who are enrolled on the study, as well confirmation that eligibility criteria for participants was being broadened out.

The initial price cap of £150 for Project Twenty21 formulary products was set to be replaced by a set £7 cost per gram of flower and per ml of oil.

However, after some patients expressed concerns about the potential price rise, Drug Science delayed the changes to allow for “discussions” with its partners to “alleviate issues where possible”.

In a newsletter which went out on Thursday 17 February, it says talks have been “going well” and it hopes to have “good news” to share soon.

It said: “We have been having further discussions with the project’s licensed-producer partners about the prescription price review. 

“This has been going well and we hope to have some good news to share with you soon but we’ve decided that there will be no change on 1 March, as we had previously announced. 

“Instead, we will let you know through our mailing list, website and Drug Science social channels when a final decision has been reached on the pricing and when it will come into force.”

Drug Science has said that the decision to alter its pricing strategy was made by its partners, who fund the project and that a change was necessary in order to allow them to continue offering high-quality products to patients and support supply going forward.

For more updates visit www.drugscience.org.uk/twenty21

• Drug Science delays Project Twenty21 pricing changes in response to patient concerns
• CBD prices falling, report suggests
• Irish patients to get cannabis-derived epilepsy drug free on health service
• What’s the difference between full-spectrum, broad-spectrum and isolate CBD?
• This is how Australia is consuming medical cannabis